Cascade, founded in December 2017, is a Sino-foreign joint venture biomedical enterprise, focusing on innovative drugs targeting nuclear receptors and G protein coupled receptors (GPCRs). The core R&D team is jointly led by internationally renowned structural biologists and top nuclear receptor scientists. The team has accumulated more than 20 years of innovative drug research and development in the fields of metabolic diseases, tumor and inflammation targeting nuclear receptors, leading the way in structure based drug design. Cascade, concentrating on independent research and development, has established a rich and risk-balanced Class 1 new drug pipeline. Currently, there are a dozen of drug candidates, of which the core product of a non-cholic acid drug molecule CS0159 targeting FXR has completed US clinical Phase 1, and Phase 2 will be initiated immediately.The orphan drug designation (ODD) for primary sclerosing cholangitis (PSC) has been granted in September of 2021.